Latest news with #SalveenRichter
Business Insider
11 hours ago
- Business
- Business Insider
Goldman Sachs Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)
In a report released today, Salveen Richter from Goldman Sachs reiterated a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $47.00. The company's shares closed today at $46.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Richter is a 4-star analyst with an average return of 8.2% and a 41.33% success rate. Richter covers the Healthcare sector, focusing on stocks such as Amgen, Biogen, and Crispr Therapeutics AG. In addition to Goldman Sachs, Crispr Therapeutics AG also received a Hold from Barclays's Gena Wang in a report issued today. However, on the same day, Needham maintained a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP). Based on Crispr Therapeutics AG's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $865 thousand and a GAAP net loss of $136 million. In comparison, last year the company earned a revenue of $504 thousand and had a GAAP net loss of $116.59 million
Yahoo
21 hours ago
- Business
- Yahoo
The Top 5 Analyst Questions From Moderna's Q1 Earnings Call
Moderna's first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations and declined sharply versus the prior year. Management attributed the performance primarily to the seasonal nature of respiratory vaccine sales and lower overall COVID vaccination rates, which have become more routine rather than urgent. CEO Stephane Bancel pointed to progress in cost reduction efforts, highlighting a 19% reduction in combined cost of sales, research and development, and selling, general and administrative expenses as a sign of ongoing financial discipline. Is now the time to buy MRNA? Find out in our full research report (it's free). Revenue: $108 million vs analyst estimates of $117.9 million (35.3% year-on-year decline, 8.4% miss) Adjusted EPS: -$2.52 vs analyst estimates of -$3.11 (18.9% beat) The company reconfirmed its revenue guidance for the full year of $2 billion at the midpoint Market Capitalization: $10.39 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Salveen Richter (Goldman Sachs) pressed for detail on the FDA's requirement for additional flu vaccine efficacy data and its impact on the timing for the flu/COVID combination, to which CEO Stephane Bancel explained the scientific rationale and anticipated review extension. Jasmine (UBS, for Eliana Merle) sought clarity on whether Phase 3 data for individualized neoantigen therapy (INT) remains on track for 2026, and inquired about trial expansion plans. President Stephen Hoge reiterated timelines are event-driven but remain possible, with further updates pending. Tyler Van Buren (TD Cowen) asked about the likelihood of approval for the next-generation COVID vaccine given recent regulatory leadership changes. Hoge responded that interactions with the FDA have been 'business as usual,' with no change in review process observed. Courtney Breen (Bernstein) questioned the drivers and flexibility behind the expanded cost-cutting program. CFO Jamey Mock explained that cost reductions are largely tied to the winding down of large Phase 3 trials and ongoing process improvements, rather than specific revenue signals. Gena Wang (Barclays) asked about U.S. COVID vaccine market share and future prospects, to which Mock replied that script data supports a stable market position and attributed lower reported revenue to customer inventory management rather than underlying loss of share. Looking ahead, the StockStory team will closely monitor (1) regulatory decisions for Moderna's next-generation COVID, RSV, and flu vaccines, (2) the pace and impact of ongoing cost reduction efforts as major clinical trials wind down, and (3) progress in late-stage pipeline programs—especially new data readouts for oncology and non-respiratory vaccines. Execution on product launches and continued market expansion will be key indicators of strategic progress. Moderna currently trades at $26.84, down from $28.58 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Business Insider
18-06-2025
- Business
- Business Insider
Evercore ISI Remains a Hold on Sarepta Therapeutics (SRPT)
Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $28.00. The company's shares closed today at $21.56. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Clark-Gartner covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Ascendis Pharma. According to TipRanks, Clark-Gartner has an average return of 4.1% and a 45.16% success rate on recommended stocks. In addition to Evercore ISI, Sarepta Therapeutics also received a Hold from Goldman Sachs's Salveen Richter in a report issued today. However, on the same day, TD Cowen maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT).
Business Insider
01-05-2025
- Business
- Business Insider
Goldman Sachs Remains a Buy on Regeneron (REGN)
Goldman Sachs analyst Salveen Richter maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of $804.00. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Richter is a 4-star analyst with an average return of 8.6% and a 41.24% success rate. Richter covers the Healthcare sector, focusing on stocks such as Regeneron, Biogen, and Crispr Therapeutics AG. In addition to Goldman Sachs, Regeneron also received a Buy from Truist Financial's Srikripa Devarakonda in a report issued yesterday. However, on the same day, UBS maintained a Hold rating on Regeneron (NASDAQ: REGN).
Bloomberg
14-02-2025
- Business
- Bloomberg
Bloomberg Markets 02/14/2025
"Bloomberg Markets" follows the market moves across every global asset class and discusses the biggest issues for Wall Street. Today's guest: Bloomberg's Mandeep Singh and Goldman Sachs US Biotechnology Lead Analyst Salveen Richter. (Source: Bloomberg)
